HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval

After a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple sclerosis candidate.

By FiercePharma · Apr 26, 2026 · via FiercePharma
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval

Image: FiercePharma

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
PipelineFiercePharma ↗
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his…
Apr 25, 2026
Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
PipelineEndpoints News ↗
Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, des…
Apr 24, 2026
PipelineAJMC ↗
…
Apr 23, 2026